Broadwood Partners, L.P. Acquires 2,420,000 Shares of OncoCyte Co. (NASDAQ:OCX) Stock

OncoCyte Co. (NASDAQ:OCX) major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of the company’s stock in a transaction dated Thursday, April 11th. The shares were bought at an average cost of $2.92 per share, for a total transaction of $7,066,400.00. Following the acquisition, the insider now owns 4,929,066 shares in the company, valued at $14,392,872.72. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

OncoCyte Stock Up 8.7 %

Shares of OCX stock opened at $2.75 on Wednesday. The company has a 50 day simple moving average of $2.96 and a two-hundred day simple moving average of $3.06. OncoCyte Co. has a 12 month low of $2.08 and a 12 month high of $6.80.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Benchmark restated a “speculative buy” rating and issued a $5.00 price target on shares of OncoCyte in a research note on Monday. StockNews.com began coverage on OncoCyte in a research report on Friday, April 12th. They issued a “sell” rating on the stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Raymond James Financial Services Advisors Inc. purchased a new position in OncoCyte during the first quarter valued at approximately $25,000. DCF Advisers LLC lifted its stake in shares of OncoCyte by 107.0% during the 1st quarter. DCF Advisers LLC now owns 25,149 shares of the company’s stock valued at $37,000 after buying an additional 13,000 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of OncoCyte during the 2nd quarter valued at $25,000. Balyasny Asset Management LLC boosted its holdings in OncoCyte by 389.9% in the 3rd quarter. Balyasny Asset Management LLC now owns 52,887 shares of the company’s stock worth $39,000 after buying an additional 42,091 shares during the period. Finally, LPL Financial LLC increased its stake in OncoCyte by 58.1% in the 2nd quarter. LPL Financial LLC now owns 108,816 shares of the company’s stock worth $98,000 after buying an additional 40,000 shares in the last quarter. 55.35% of the stock is owned by hedge funds and other institutional investors.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.